News & Updates

Alirocumab prior to PCI lowers LDL-C

18 Oct 2022 by

Starting alirocumab early in the hospital prior to undergoing percutaneous coronary intervention (PCI) reduces LDL-cholesterol (LDL-C) in STEMI* patients already on high-statin therapy.

Alirocumab prior to PCI lowers LDL-C

18 Oct 2022

Multimodal thrombectomy device holds promise in DVT treatment

17 Oct 2022 by

A novel thrombectomy device using a sequestered approach delivers positive clinical outcomes in the treatment of high-risk, large-volume deep vein thrombosis (DVT), according to a study.

Multimodal thrombectomy device holds promise in DVT treatment

17 Oct 2022

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

Updated BEST results: No major difference between EES or CABG for multivessel disease

14 Oct 2022 by

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

Updated BEST results: No major difference between EES or CABG for multivessel disease

14 Oct 2022

Hypertension shows weak to no link to cognition in late life

13 Oct 2022

There appears to only be a very weak to no significant correlation between hypertension and cognitive function in late life, reports a recent study.

Hypertension shows weak to no link to cognition in late life

13 Oct 2022

Cuff-based SBP amplification shows bias, less variability

13 Oct 2022

Cuff-based estimates of systolic blood pressure (SBP) amplification demonstrate proportional systematic bias and less individual variability regardless of the difference from invasive measurements, according to a recent study.

Cuff-based SBP amplification shows bias, less variability

13 Oct 2022

Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension

13 Oct 2022

The combination of digital therapeutics (DTx) with the treatment-as-usual (TAU) strategy for essential hypertension is more cost-effective than TAU alone, a recent Japan study has found.

Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension

13 Oct 2022

Early noninferior to delayed NOAC initiation after stroke in AF patients

13 Oct 2022

Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.

Early noninferior to delayed NOAC initiation after stroke in AF patients

13 Oct 2022

Depression tied to cold-induced blood pressure elevation

12 Oct 2022

Individuals with depressive symptoms are more susceptible to cold-induced increase in their blood pressure (BP) compared to nondepressive counterparts, suggests a Japan study.

Depression tied to cold-induced blood pressure elevation

12 Oct 2022

Telmisartan does not deliver in peripheral arterial disease

11 Oct 2022

Treatment with the angiotensin receptor blocker telmisartan does not appear to confer improvements on walking performance in patients with lower extremity peripheral artery disease (PAD), according to the TELEX trial.

Telmisartan does not deliver in peripheral arterial disease

11 Oct 2022

News & Updates

Filter by Specialty:

Specialty:

Alirocumab prior to PCI lowers LDL-C

Alirocumab prior to PCI lowers LDL-C

Multimodal thrombectomy device holds promise in DVT treatment

Multimodal thrombectomy device holds promise in DVT treatment

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

Updated BEST results: No major difference between EES or CABG for multivessel disease

Updated BEST results: No major difference between EES or CABG for multivessel disease

Hypertension shows weak to no link to cognition in late life

Hypertension shows weak to no link to cognition in late life

Cuff-based SBP amplification shows bias, less variability

Cuff-based SBP amplification shows bias, less variability

Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension

Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension

Early noninferior to delayed NOAC initiation after stroke in AF patients

Early noninferior to delayed NOAC initiation after stroke in AF patients

Depression tied to cold-induced blood pressure elevation

Depression tied to cold-induced blood pressure elevation

Telmisartan does not deliver in peripheral arterial disease

Telmisartan does not deliver in peripheral arterial disease